Eli Lilly’s fourth-quarter earnings surpassed market forecasts, buoyed by robust sales of Zepbound and Mounjaro, leading to $9.35 billion in revenue. However, the company’s stock experienced a slight downturn following the earnings announcement. Eli Lilly remains optimistic for 2024, expecting continued growth in sales and revenue. Find out more on FinanceVoyager